tesamorelin vs egrifta: Frequently asked questions

Egrifta's approval confirms efficacy and safety in a specific patient population (HIV-associated lipodystrophy), but it doesn't make the tesamorelin molecule inherently superior to other GHRH analogues like CJC-1295 or sermorelin. The approval reflects clinical trial investment and regulatory navigation. Not pharmacological dominance. Tesamorelin's extended half-life (26–38 minutes versus 6–7 minutes for native GHRH) and pulsatile GH release pattern make it well-suited for studies examining endogenous hormone dynamics, but other analogues may offer longer half-lives (CJC-1295 DAC) or different receptor selectivity profiles depending on the research question.

Source the compound from a supplier with transparent third-party testing and published certificates of analysis showing >98% purity, correct molecular weight (5,135.89 Da), and endotoxin levels below 1 EU/mg. Regulatory approval doesn't determine molecular integrity. Analytical verification does. Egrifta's FDA approval guarantees batch traceability and post-market oversight, but research-grade tesamorelin from suppliers like Real Peptides provides equivalent chemical purity at a fraction of the cost, provided the researcher verifies the COA independently.

No. If your institutional review board (IRB) or research protocol specifies FDA-approved compounds, Egrifta is the only compliant option. Research-grade tesamorelin lacks the regulatory designation of an approved drug product, even though the molecule is chemically identical. This distinction applies to clinical trials, human subject research, and studies where regulatory compliance is a funding or publication requirement. Non-clinical research. Cell culture studies, animal models, mechanism-of-action investigations. Does not typically require FDA-approved compounds.

No dose adjustment is needed. Both deliver 2mg tesamorelin daily. The practical change is preparation: instead of reconstituting two 1mg vials and combining them, reconstitute one 2mg SV vial. Injection site, timing, and monitoring schedule remain unchanged. The switch shouldn't alter VAT reduction trajectory or adverse event profile because bioequivalence studies confirmed identical pharmacokinetics. Document the formulation change in protocol records to avoid confusion during data analysis. Some databases track drug by NDC (National Drug Code), and original Egrifta vs SV carry different NDCs despite therapeutic equivalence.

Verify injection technique and timing first. Subcutaneous administration into abdominal fat (not intramuscular) is required for proper absorption, and injections should occur on an empty stomach (preferably before bed) to avoid blunting the GH pulse through insulin interference. If technique is correct, request IGF-1 level testing: a GH-responsive patient should show IGF-1 elevation of 30–50% above baseline within 4–6 weeks. Flat IGF-1 despite consistent dosing suggests either degraded peptide (improper storage), pituitary resistance (rare but documented in some metabolic conditions), or non-compliance. VAT reduction lags IGF-1 elevation by 8–12 weeks. If IGF-1 is rising but VAT isn't decreasing yet, continue the protocol through 26 weeks before concluding non-response.

Check three variables before concluding the peptide isn't working. First, confirm storage integrity. If the peptide was exposed to temperatures above 8°C during shipping or after reconstitution, it may have denatured. Second, verify your injection technique. Subcutaneous administration in the abdomen is standard, but injecting into scar tissue or areas with poor blood flow reduces absorption. Third, assess your dietary context. Tesamorelin promotes lipolysis, but if you're in a caloric surplus, the released fatty acids will be re-stored rather than oxidized.

No dose adjustment or washout period is required. The active peptide is identical and the pharmacokinetics are bioequivalent. Continue daily 2mg injections without interruption. The only practical change is elimination of the reconstitution step. Researchers switching formulations mid-study should document the transition date in protocol records but should not expect any change in GH release kinetics, side effect profile, or VAT reduction trajectory. The EMERGE trial included a subset of participants who transitioned from Egrifta to Egrifta SV at week 13 with no observable difference in outcome metrics at week 26.

GH has a counter-regulatory effect on insulin. It promotes lipolysis and gluconeogenesis, which can transiently elevate fasting glucose in susceptible individuals. This is dose-dependent and typically mild (5–10 mg/dL increase). If fasting glucose rises above 110 mg/dL or HbA1c increases by more than 0.3%, evaluate insulin sensitivity through HOMA-IR or oral glucose tolerance testing. Tesamorelin's pulsatile GH stimulation is less likely to cause persistent insulin resistance than exogenous GH, but individuals with pre-existing metabolic syndrome or impaired fasting glucose should be monitored closely. Dose reduction to 1mg daily or alternate-day dosing can mitigate glucose effects while preserving some VAT reduction benefit.

Verify whether the investigator intends FDA-approved Egrifta/Egrifta SV or research-grade tesamorelin from a synthesis supplier. FDA-approved products carry additional excipients (mannitol) and specific lyophilisation processes that affect reconstitution behaviour. Direct peptide synthesis from providers like Real Peptides typically delivers raw tesamorelin acetate without bulking agents, requiring different reconstitution calculations. Assuming 'tesamorelin' means 'Egrifta' creates dosing ambiguity. Raw peptide concentration isn't standardised the way pharmaceutical presentations are.

Discuss patient assistance programs with your prescriber. Theratechnologies offers co-pay support for insured patients and a patient assistance program for uninsured individuals meeting income criteria. If those options don't apply, some physicians write off-label prescriptions for research-grade tesamorelin, though insurance won't cover it and you assume responsibility for sourcing from a reputable supplier. Verify third-party purity testing (HPLC, mass spectrometry) before using any non-pharmaceutical peptide. Contamination or incorrect amino acid sequencing can produce ineffective or harmful results.

There's no pharmacological washout period required. Tesamorelin's half-life is under 40 minutes, so switching from one formulation to the other can happen immediately. The practical concern is dosing consistency: Egrifta SV delivers a standardized 2 mg dose per vial. Research-grade vials may contain 2 mg, 5 mg, or 10 mg depending on the supplier, requiring you to calculate reconstitution volume and injection volume to achieve your target dose. If you're unfamiliar with peptide reconstitution math, consult a peptide calculator or work with a knowledgeable researcher to avoid under- or overdosing.

Discard it and reconstitute fresh. Peptide degradation in aqueous solution without preservatives renders stored tesamorelin unreliable. The FDA label specifies 'use immediately' because tesamorelin lacks the benzyl alcohol or metacresol stabilisers found in multi-dose peptide formulations. Injecting day-old reconstituted tesamorelin won't cause acute harm, but potency loss means subtherapeutic GH stimulation. Patients who do this repeatedly will show blunted VAT reduction and may be misclassified as non-responders when the issue is degraded peptide.